Skip to NavigationSkip to content

GW Pharma takes back control of UK Sativex sales from Bayer

Published on 02/03/20 at 11:40am

British firm GW Pharmaceuticals has revealed that it plans to reclaim the commercialisation rights to market its cannabis-based multiple sclerosis drug Sativex (delta-9-tetrahydrocannabinol and cannabidiol), known by the generic name nabiximols, in the UK.

Previously, all sales in the UK of Sativex were exclusively managed by GW Pharma’s partner Bayer; this has been the case since the drug’s approval in 2010 by the

 Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of spasticity originating from multiple sclerosis.

However, this model will change going forward. As of the new arrangement agreed between GW and Bayer, there will be a “transitional period” until the end of this year, with GW assuming all commercialisation responsibilities relating to the sale of Sativex beyond 31 December 2020.

The pair committed to maintain “a seamless transition for health care professionals and patients” during this interim period, with no planned changes to day-to-day business practice.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches